Immunomodulation with Adjuvants and Cytokines

Dae Won Kim, Adi Diab

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The discovery of key regulators of T cell response and the development of checkpoint inhibitors has led to a paradigm shift in cancer therapy. Immune checkpoint inhibitors have demonstrated remarkable tumor shrinkage and durable clinical activity. However, the clinical benefits from checkpoint inhibitors are limited to selected patients, possibly due to insufficient antitumor T cell responses and/or lack of effector T cell infiltration into tumors. Cancer vaccines with adjuvants can overcome these obstacles by inducing potent antitumor T cell responses and effector T cell infiltration into the tumor. Although preclinical data showed promising results with cancer vaccines, only a few of them have demonstrated limited success in clinical studies, likely due to weak vaccine adjuvants. Adjuvants and cytokines are essential to enhance the potency and longevity of the antitumor immunity induced by cancer vaccines. Here, we discuss current practical applications of diverse adjuvants and cytokines.

Original languageEnglish (US)
Title of host publicationImmunotherapy in Translational Cancer Research
PublisherWiley-Blackwell
Pages115-131
Number of pages17
ISBN (Electronic)9781118684535
ISBN (Print)9781118123225
DOIs
StatePublished - Apr 13 2018
Externally publishedYes

Keywords

  • Adjuvants
  • Cytokines
  • Immunotherapy

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Immunomodulation with Adjuvants and Cytokines'. Together they form a unique fingerprint.

Cite this